celiprolol has been researched along with Angina Pectoris in 27 studies
Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.
Angina Pectoris: The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The comparative antianginal effects and safety of propranolol and celiprolol, a highly beta 1-selective adrenoceptor blocker with selective partial beta 2-adrenoceptor agonist activity, were assessed in an international multicenter, placebo run-in, active control, double-blind, randomized, titration-to-effect study of 140 patients with stable, exercise-induced angina pectoris." | 9.07 | Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol International Angina Study Group. ( Eff, J; Frishman, WH; Greenberg, S; Heiman, M; Soberman, J, 1991) |
| "This double-blind, placebo-controlled, parallel, multicenter study was designed to evaluate the anti-anginal and anti-ischemic effects of celiprolol in patients with stable, exercise-induced angina pectoris." | 9.06 | Celiprolol in angina pectoris: a controlled study. ( Capone, P; Eff, J; Garutti, R; Godfrey, J, 1986) |
| "A multicenter, double-blind placebo controlled study was designed to examine the efficacy of celiprolol in exercise induced angina pectoris." | 9.06 | Celiprolol in the treatment of exercise induced angina pectoris. ( Capone, P; Mayol, R, 1986) |
| "Once-daily atenolol and celiprolol were compared in a placebo-controlled crossover study of 16 patients with stable angina pectoris." | 9.06 | Atenolol and celiprolol for stable angina pectoris. ( Dargie, HJ; Findlay, IN; Henderson, E; McLenachan, JM; Wilson, JT, 1988) |
| "Celiprolol was found to be an effective antianginal agent compared with placebo." | 7.76 | Celiprolol in angina pectoris. ( Frishman, WH; Soberman, JE, 1988) |
| "In 30 hypertensives with angina pectoris the acute action of beta-blockers Celiprolol and Metoprolol on the global and coronary haemodynamics was tested within cardiac catheter diagnostics." | 7.68 | [Acute changes of coronary and global hemodynamics in patients with angina pectoris and arterial hypertension caused by celiprolol and metoprolol]. ( Bruch, L; Franz, N; Gola, G; Heublein, B; Linss, G; Modersohn, D; Walde, T, 1990) |
| "In the present study, the beta-receptor-blocker Celiprolol was tested for its antianginal effects during an observation period of 12 months; 29 patients, both male and female, with definite coronary heart diseases, were subjected to this study." | 7.67 | [Treatment of coronary heart disease with the beta-1-receptor blocker celiprolol in a long-term study over a 12-month period]. ( Klinger, D, 1987) |
| "Celiprolol has shown equivalent antihypertensive efficacy to other beta-blockers, notably propranolol, atenolol, metoprolol and pindolol, in patients aged 18 to 75 years with mild to moderate essential hypertension." | 6.39 | Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. ( Dunn, CJ; Spencer, CM, 1995) |
| "Celiprolol has been demonstrated to have antianginal and anti-ischemic effects comparable with both propranolol and atenolol, with a decreased incidence of bradycardia noted in the celiprolol-treated cohorts." | 6.38 | Clinical performance and therapeutic potential of celiprolol in angina pectoris. ( Frishman, WH; Soberman, JE, 1989) |
| " If the apparent pharmacodynamic advantages of celiprolol are confirmed in well designed therapeutic trials then celiprolol should represent a definite advance in beta-adrenoceptor blocking therapy." | 6.37 | Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. ( Brogden, RN; Riddell, JG; Shanks, RG, 1987) |
| "The comparative antianginal effects and safety of propranolol and celiprolol, a highly beta 1-selective adrenoceptor blocker with selective partial beta 2-adrenoceptor agonist activity, were assessed in an international multicenter, placebo run-in, active control, double-blind, randomized, titration-to-effect study of 140 patients with stable, exercise-induced angina pectoris." | 5.07 | Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol International Angina Study Group. ( Eff, J; Frishman, WH; Greenberg, S; Heiman, M; Soberman, J, 1991) |
| "This double-blind, placebo-controlled, parallel, multicenter study was designed to evaluate the anti-anginal and anti-ischemic effects of celiprolol in patients with stable, exercise-induced angina pectoris." | 5.06 | Celiprolol in angina pectoris: a controlled study. ( Capone, P; Eff, J; Garutti, R; Godfrey, J, 1986) |
| "A multicenter, double-blind placebo controlled study was designed to examine the efficacy of celiprolol in exercise induced angina pectoris." | 5.06 | Celiprolol in the treatment of exercise induced angina pectoris. ( Capone, P; Mayol, R, 1986) |
| "The effects of once-daily dosing with celiprolol 200 mg, celiprolol 400 mg, and atenolol 100 mg have been studied in 19 male patients with chronic stable angina pectoris." | 5.06 | A single-blind randomized comparison of the 24-h antianginal efficacy of celiprolol versus atenolol. ( Jackson, NC; Lee, PS; Taylor, SH, 1986) |
| "Once-daily atenolol and celiprolol were compared in a placebo-controlled crossover study of 16 patients with stable angina pectoris." | 5.06 | Atenolol and celiprolol for stable angina pectoris. ( Dargie, HJ; Findlay, IN; Henderson, E; McLenachan, JM; Wilson, JT, 1988) |
| "Celiprolol (400 mg) and atenolol (100 mg) were given once a day to 16 patients with stable angina pectoris in a double blind placebo controlled crossover study." | 5.06 | Importance of ancillary properties of beta blockers in angina: a study of celiprolol and atenolol. ( Dargie, HJ; McLenachan, JM; Wilson, JT, 1988) |
| "The results of an extensive pre-clinical and clinical research programme indicate that celiprolol is a safe and effective treatment for both hypertension and angina pectoris." | 5.06 | Celiprolol--overview of 6 years of clinical trials experience. ( Hagen, NS; Lamon, KD; Pruss, TP, 1988) |
| "Celiprolol is a hydrophilic, beta 1-selective adrenoceptor antagonist with mild selective beta 2-agonist as well as weak vasodilator properties." | 3.77 | Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. ( Buckley, MM; Milne, RJ, 1991) |
| "Celiprolol was found to be an effective antianginal agent compared with placebo." | 3.76 | Celiprolol in angina pectoris. ( Frishman, WH; Soberman, JE, 1988) |
| " The adverse experience safety data derived from 18 double-blind trials (n = 2884) were evaluated." | 3.76 | Safety profile of celiprolol. ( Lamon, KD, 1988) |
| "In 30 hypertensives with angina pectoris the acute action of beta-blockers Celiprolol and Metoprolol on the global and coronary haemodynamics was tested within cardiac catheter diagnostics." | 3.68 | [Acute changes of coronary and global hemodynamics in patients with angina pectoris and arterial hypertension caused by celiprolol and metoprolol]. ( Bruch, L; Franz, N; Gola, G; Heublein, B; Linss, G; Modersohn, D; Walde, T, 1990) |
| "In the present study, the beta-receptor-blocker Celiprolol was tested for its antianginal effects during an observation period of 12 months; 29 patients, both male and female, with definite coronary heart diseases, were subjected to this study." | 3.67 | [Treatment of coronary heart disease with the beta-1-receptor blocker celiprolol in a long-term study over a 12-month period]. ( Klinger, D, 1987) |
| "Celiprolol is a novel beta 1 selective adrenoreceptor blocker with partial beta 2 agonism and direct vasodilator activity." | 2.67 | Cardiorespiratory and symptomatic variables during maximal and submaximal exercise in men with stable effort angina: a comparison of atenolol and celiprolol. ( Christie, J; Dargie, HJ; Ford, I; Grant, S; Henderson, E; MacFarlane, N; McCann, G; Norrie, J; Ray, SG, 1994) |
| "Celiprolol is a third generation beta blocking drug with intrinsic vasodilator effect." | 2.67 | [Celiprolol in the treatment of chronic stable angina]. ( Cuevas, G; Martínez, D; Román, O; Vargas, W, 1991) |
| "Celiprolol is a cardioselective beta-adrenoceptor antagonist with attributed cardiostimulant properties." | 2.66 | Comparative effects of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercise-induced angina. ( Frais, MA; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1986) |
| "A new cardioselective betablocker, celiprolol (C) in a dosage of 100 mg t." | 2.65 | [Double-blind, placebo-controlled trial of propranolol vs celiprolol in stable effort angina: antianginal efficacy and side effects ]. ( Brandt, D; Fluch, N; Klein, W, 1982) |
| "Celiprolol has shown equivalent antihypertensive efficacy to other beta-blockers, notably propranolol, atenolol, metoprolol and pindolol, in patients aged 18 to 75 years with mild to moderate essential hypertension." | 2.39 | Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. ( Dunn, CJ; Spencer, CM, 1995) |
| "Celiprolol has been demonstrated to have antianginal and anti-ischemic effects comparable with both propranolol and atenolol, with a decreased incidence of bradycardia noted in the celiprolol-treated cohorts." | 2.38 | Clinical performance and therapeutic potential of celiprolol in angina pectoris. ( Frishman, WH; Soberman, JE, 1989) |
| " If the apparent pharmacodynamic advantages of celiprolol are confirmed in well designed therapeutic trials then celiprolol should represent a definite advance in beta-adrenoceptor blocking therapy." | 2.37 | Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. ( Brogden, RN; Riddell, JG; Shanks, RG, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (59.26) | 18.7374 |
| 1990's | 11 (40.74) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klein, W | 1 |
| Fluch, N | 1 |
| Brandt, D | 1 |
| Ray, SG | 1 |
| McCann, G | 1 |
| Henderson, E | 2 |
| MacFarlane, N | 1 |
| Christie, J | 1 |
| Norrie, J | 1 |
| Ford, I | 1 |
| Grant, S | 2 |
| Dargie, HJ | 5 |
| Dunn, CJ | 1 |
| Spencer, CM | 1 |
| Frishman, WH | 4 |
| McLenachan, J | 2 |
| Heiman, M | 1 |
| Soberman, J | 1 |
| Greenberg, S | 1 |
| Eff, J | 3 |
| Norris, RJ | 1 |
| Silke, B | 2 |
| Verma, SP | 2 |
| Guy, S | 1 |
| Román, O | 1 |
| Cuevas, G | 1 |
| Martínez, D | 1 |
| Vargas, W | 1 |
| Milne, RJ | 1 |
| Buckley, MM | 1 |
| McLenachan, JM | 4 |
| Franz, N | 1 |
| Modersohn, D | 1 |
| Linss, G | 1 |
| Heublein, B | 1 |
| Gola, G | 1 |
| Bruch, L | 1 |
| Walde, T | 1 |
| Godfrey, J | 1 |
| Garutti, R | 1 |
| Capone, P | 3 |
| Mayol, R | 1 |
| Jackson, NC | 1 |
| Lee, PS | 1 |
| Taylor, SH | 2 |
| Soberman, JE | 2 |
| Harston, WE | 1 |
| Klinger, D | 1 |
| Riddell, JG | 1 |
| Shanks, RG | 1 |
| Brogden, RN | 1 |
| Findlay, IN | 1 |
| Wilson, JT | 3 |
| Wilson, J | 1 |
| Dargie, H | 2 |
| Lamon, KD | 2 |
| Pruss, TP | 1 |
| Hagen, NS | 1 |
| Frais, MA | 1 |
| Reynolds, G | 1 |
9 reviews available for celiprolol and Angina Pectoris
| Article | Year |
|---|---|
Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.
Topics: Administration, Oral; Angina Pectoris; Antihypertensive Agents; Celiprolol; Humans; Hypertension; Ra | 1995 |
Clinical perspective on celiprolol: cardioprotective potential.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Asthma; Blood Pressure; Celiprolol; Coronary Disease; | 1991 |
Efficacy of celiprolol in hypertension and angina pectoris. Introduction.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Celiprolol; Humans; Hypertens | 1991 |
Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Antihypertensive Agents; Celiprolol; Dogs; He | 1991 |
A review of the clinical experience with celiprolol in angina.
Topics: Angina Pectoris; Antihypertensive Agents; Celiprolol; Humans; Propanolamines | 1991 |
Clinical performance and therapeutic potential of celiprolol in angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Celiprolol; Humans; Propanolamines | 1989 |
Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Celiprolol; Hemodynamics; Humans; Hypertensio | 1987 |
Celiprolol in angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Celiprolol; Clinical Trials as Topic; Double | 1988 |
Safety profile of celiprolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Atenolol; Celiprolol; Chlorth | 1988 |
19 trials available for celiprolol and Angina Pectoris
| Article | Year |
|---|---|
[Double-blind, placebo-controlled trial of propranolol vs celiprolol in stable effort angina: antianginal efficacy and side effects ].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Celiprolol; Clinical Trials as Topic; | 1982 |
Cardiorespiratory and symptomatic variables during maximal and submaximal exercise in men with stable effort angina: a comparison of atenolol and celiprolol.
Topics: Aged; Angina Pectoris; Atenolol; Celiprolol; Cross-Over Studies; Double-Blind Method; Electrocardiog | 1994 |
Angina, ischemia, and effort tolerance with vasodilating beta-blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Cardiac Output; Celiprolol; Coronary Disease | 1991 |
Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol International Angina Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Analysis of Variance; Angina Pectoris; | 1991 |
Hemodynamic interactions of a new beta blocker, celiprolol, with nifedipine in angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Celiprolol; Drug Interactions; Drug Therapy, Co | 1991 |
[Celiprolol in the treatment of chronic stable angina].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angina Pectoris; Celiprolol; Female; He | 1991 |
Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Antihypertensive Agents; Celiprolol; Dogs; He | 1991 |
Celiprolol in angina pectoris: a controlled study.
Topics: Adult; Aged; Angina Pectoris; Celiprolol; Clinical Trials as Topic; Double-Blind Method; Electrocard | 1986 |
Celiprolol in the treatment of exercise induced angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Celiprolol; Clinical Trials as Topic; Dou | 1986 |
A single-blind randomized comparison of the 24-h antianginal efficacy of celiprolol versus atenolol.
Topics: Angina Pectoris; Atenolol; Celiprolol; Clinical Trials as Topic; Exercise Test; Humans; Propanolamin | 1986 |
A double blind placebo controlled study of celiprolol in the treatment of angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Celiprolol; Clinical Trials as Topic; Double-Blind Met | 1985 |
Atenolol and celiprolol for stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Celiprolol; Clinical Trials as | 1988 |
Importance of ancillary properties of beta blockers in angina: a study of celiprolol and atenolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Blood Pressure; Celiprolol; Cli | 1988 |
Celiprolol in angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Celiprolol; Clinical Trials as Topic; Double | 1988 |
Improved left ventricular function during exercise: a comparison of celiprolol and atenolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Cardiac Output; Celiprolol; Exercise; Exerci | 1988 |
Safety profile of celiprolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Atenolol; Celiprolol; Chlorth | 1988 |
Celiprolol--overview of 6 years of clinical trials experience.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Celiprolol; Clinical Trials as Topic; Humans; Hyperten | 1988 |
Celiprolol and atenolol in angina--effects on left ventricular function.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Celiprolol; Clinical Trials as | 1988 |
Comparative effects of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercise-induced angina.
Topics: Angina Pectoris; Celiprolol; Chromatography, Gas; Chromatography, High Pressure Liquid; Drug Evaluat | 1986 |
2 other studies available for celiprolol and Angina Pectoris
| Article | Year |
|---|---|
[Acute changes of coronary and global hemodynamics in patients with angina pectoris and arterial hypertension caused by celiprolol and metoprolol].
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Celiprolol; Hemodynamics; Humans; Hypertension; | 1990 |
[Treatment of coronary heart disease with the beta-1-receptor blocker celiprolol in a long-term study over a 12-month period].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Celiprolol; Coronary Disease; Electrocard | 1987 |